A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
← catalyst calendarNCT06793709 · readout in 2,285 d
Sponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
60estimated
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-10 | actual | When the study began enrolling |
| Primary completion | 2032-11-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-11-20 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Biliary Tract Cancer
Intervention
- Other: No Intervention
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Adverse Drug Reactions
measured Up to 1 year
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed